On Friday, November 22, CCL Senior Litigation Attorney Louis Bograd spoke on developments in generic drug preemption litigation in the wake of the U.S. Supreme Court’s Mensing and Bartlett decisions, the former of which Bograd argued before the high court, at the Louisiana State Bar Association’s Complex Litigation/Class Action Symposium in New Orleans. The featured presentation by Bograd occurred on a panel on “Recent Preemption Activity: Drugs, Devices & Generics." Recently, the Food and Drug Administration proposed new regulations, now undergoing a comment period, that would effectively reverse Mensing and subject generic drug manufacturers to the same responsibilities to warn consumers of adverse risks that name-brand manufacturers must discharge.